Quick Answer
iBio, Inc. reported Total Revenue of $400.0 thousand for the year ending 2025.
- iBio, Inc. showed an increase of +77.8% in Total Revenue from 2024 to 2025.
- This data is from iBio, Inc.'s annual report (Form 10-K), filed with the SEC on September 5, 2025.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $122.0 thousand | Q4 2017: $153.0 thousand | Q1 2018: $78.0 thousand | Q3 2018: $45.0 thousand | Q4 2018: $651.0 thousand | Q1 2019: $527.0 thousand | Q3 2019: $108.0 thousand | Q4 2019: $314.0 thousand | Q1 2020: $96.0 thousand | Q3 2020: $410.0 thousand | Q4 2020: $705.0 thousand | Q1 2021: $765.0 thousand | Q3 2021: $84.0 thousand | Q4 2021: $0.00 | Q1 2022: $1.80 million | Q3 2022: $0.00 | Q4 2022: $0.00 | Q1 2023: $0.00 | Q3 2023: $50.0 thousand | Q3 2023: $50.0 thousand | Q3 2024: $0.00 | Q4 2024: $200.0 thousand | Q1 2025: $0.00 | Q3 2025: $100.0 thousand | Q4 2025: $0.00.
- Over the full 10 years of available data (2017 to 2025), iBio, Inc.'s Total Revenue has grown by 1.5%.
- Historical annual values: Fiscal year 2025: $400.0 thousand | Fiscal year 2024: $225.0 thousand | Fiscal year 2023: $0.00 | Fiscal year 2023: $0.00 | Fiscal year 2022: $1.88 million | Fiscal year 2021: $2.37 million | Fiscal year 2020: $1.64 million | Fiscal year 2019: $2.02 million | Fiscal year 2018: $444.0 thousand | Fiscal year 2017: $394.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: